Prognostic factors and staging in multiple myeloma.
The field of multiple myeloma prognostication is replete with studies that have shown the value of independent predictors in determining clinical outcome. It is clear that host factors and factors intrinsic to the cells are the ultimate determinants of prognosis. In the immediate period after diagnosis, those factors related to the host are likely to be more relevant, whereas with passing time factors intrinsic to the cells predominate. At a minimum, we recommend that a comprehensive molecular cytogenetic assessment be performed at diagnosis, together with conventional evaluation, including beta2-microglobulin and albumin. In addition, information on proliferative activity of plasma cells may be of value. The introduction of novel methods of prognostication should be strongly considered in all clinical trials.
Fonseca
Rafael
R
Mayo Clinic Arizona, 13208 East Shea Boulevard, Collaborative Research Building, 3-006, Scottsdale, AZ 85259-5494, USA. fonseca.rafael@mayo.edu
San Miguel
Jesus
J
D015415:Biomarkers / Q000097:blood / Q000652:urine; D002882:Chromosomes, Human, Pair 13; D018450:Disease Progression; D004358:Drug Therapy / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D009101:Multiple Myeloma / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging / Q000379:methods*; D010641:Phenotype; D011379:Prognosis
D015415:Biomarkers